Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE CYSTO versus IOMERVU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE CYSTO versus IOMERVU.
HYPAQUE-CYSTO vs IOMERVU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Iodinated radiocontrast agent that attenuates X-rays by increasing radiopacity of blood vessels and tissues, allowing visualization during imaging procedures.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
Intravenous: 0.5-2 mL/kg of iomeprol 300-400 mg I/mL for imaging, not exceeding 200 mL total dose; arterial: up to 250 mL per procedure.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In renal impairment, half-life is prolonged (up to 10-30 hours in severe impairment), necessitating dose adjustment and monitoring. The half-life is not significantly affected by hepatic impairment.
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Iomeprol is almost exclusively eliminated via renal glomerular filtration, with 92-98% of the administered dose recovered unchanged in urine within 24 hours. Less than 2% is excreted in feces via biliary elimination. In patients with normal renal function, renal clearance approximates glomerular filtration rate.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent